Dietary supplementation of Omega 3 and the participation in the placentary vascular resistance mechanism in pregnant people: a comparison with normal pregnant women without use of Omega, chronic hypertensions in use of AAS and pregnants with thrombophilia and use Heparina or AAS - OMGAREV TRIAL: Use of Omega and Placental Vascular Resistance

Faculdade de Medicina de Barbacena0 个研究点开始时间: 2018年6月19日最近更新: 2023年5月29日

适应症

试验速览

暂无简介。

•Pregnant women enrolled in prenatal care of the institution.
•Pregnant women who signed the free and informed consent form.
•Pregnant women who attend the appointments (with even a missed prenatal) and agree to perform the protocol of the service, clinical examinations and imaging.
•Pregnant women with hereditary or acquired thrombophilias identified
•previously.
•Pregnant women with identified risk factor for preeclampsia or CIUR selected from ACOG and NICE data adapted for this study:
•i. Identification of two anamnesis clinical data (clinical history of PE in previous pregnancy, history
•PE in first-degree relative, BMI> 35 kg / m2, hypertension, nephropathy, disease
•autoimmune).
•ii. Identification of anamnesis clinical data associated with changes in uterine artery doppler in the
•first trimester (IR, PI or bilateral doppler notch).
•iii. MAP identification> 100 in the first trimester of pregnancy associated with clinical history or Doppler
•altered uterine artery (PI, IR, uterine artery notch).

•Pregnant women - under 19 years.
•Pregnant women who are absent from consultations - two or more consecutive prenatal absences.
•Pregnant women who do not accept to use the omega in the prenatal or have intolerance to the use of the omega.
•Smoking patients.
•Gestantes without risk factor or thrombophilia.

发起方

Faculdade de Medicina de Barbacena